Alimera Sciences Stock
Alimera Sciences Stock
Our community is currently high on Alimera Sciences with 3 Buy predictions and 0 Sell predictions.
With a target price of 6 € there is a positive potential of 45.72% for Alimera Sciences compared to the current price of 4.12 €.
Pros and Cons of Alimera Sciences in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Alimera Sciences | - | - | - | - | - | - | - |
Gritstone Oncology Inc | 7.500% | 11.232% | -68.609% | -64.385% | -58.692% | -90.478% | - |
Avid Bioservices Inc | 5.380% | 15.126% | 7.031% | -56.090% | 12.295% | -61.517% | 57.743% |
Pacira Pharmaceuticals | 1.690% | -0.826% | -8.397% | -39.698% | -19.463% | -54.286% | -31.799% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at Alliance Global Partners from a "neutral" rating to a "buy" rating.
Show more
Ratings data for ALIM provided by MarketBeat